Donald Ludovici

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants

Kalyan Das, Arthur D. Clark, Paul Lewi et al. · Journal of Medicinal Chemistry · 2004 · 511 citations

TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Koen Andries, Hilde Azijn, Theo Thielemans et al. · Antimicrobial Agents and Chemotherapy · 2004 · 322 citations · Full text

Immunology, Pharmacotherapy, Antiviral Drug +17

Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues

Donald Ludovici, Bart L. De Corte, Michael J. Kukla et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 184 citations

Anti-hiv Drug Candidates, Medicine, Antiviral Drug Development +10

Evolution of Anti-HIV Drug CandidatesPart 2: Diaryltriazine (DATA) Analogues

Donald Ludovici, Robert W. Kavash, Michael J. Kukla et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 125 citations

Medicinal Chemistry, Medicine, Antiviral Drug Development +7

Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) Derivatives. 3

Henry J. Breslin, Michael J. Kukla, Donald Ludovici et al. · Journal of Medicinal Chemistry · 1995 · 97 citations